Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 19, 2017

View Archived Issues

Complete remissions maintained with blinatumomab in acute lymphocytic leukemia patients

CRAFT computational approach identifies new targets for treating epilepsy

Phase II data does not support adding CC-486 to fulvestrant for ER+ HER2-metastatic breast cancer

NCI recruiting participants in phase I trial of Aza-TdC in patients with solid tumors

Fresenius submits first biosimilar MAA to EMA

Phase II trial of LJPC-401 in hereditary hemochromatosis begins

Bristol-Myers Squibb's Yervoy recommended for approval in Europe for pediatric melanoma

ISA and Regeneron collaborate to study ISA-101 with cemiplimab in head and neck and cervical cancers

European MAA for patisiran submitted by Sanofi and Alynylam

FDA grants priority review to Opdivo plus Yervoy sBLA for advanced renal cell carcinoma

MHRA partners with WHO and Gates Foundation to improve safety monitoring

Achillion Pharmaceuticals' ACH-4471 receives U.S. orphan drug designation

EMA committee recommends against approval of Aplidin for multiple myeloma.

Orchard Therapeutics contracts Yposkesi for lentiviral vector batches

Ultragenyx Pharmaceutical sells Rare Pediatric Disease Priority Review Voucher to Novartis

GC-4419 meets primary endpoint in phase II trial of oral mucositis in chemotherapy patients

SF-0166 well tolerated in phase I/II wet AMD trial

Netarsudil ophthalmic solution approved in the U.S. for lowering intraocular pressure

BLA accepted for Teva's fremanezumab

RXI-109 improves revision of hypertrophic scars in phase II trial

FDA breakthrough designation granted for fingolimod for pediatric multiple sclerosis

FDA Fast Track designation granted to elamipretide for Leber's hereditary optic neuropathy

Kalyra Pharmaceuticals divulges novel EGFR inhibitors

Constellation Pharmaceuticals, Genentech patent CREB-binding protein/EP300 inhibitors

KalVista Pharmaceuticals identifies novel plasma kallikrein inhibitors

New histone demethylase inhibitors synthesized at Oryzon Genomics

Taiho Pharmaceutical discovers new ribonucleoside-diphosphate reductase inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...